View ValuationVictrex 将来の成長Future 基準チェック /36Victrex利益と収益がそれぞれ年間96%と4.5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に14.3% 75.7%なると予測されています。主要情報96.0%収益成長率75.69%EPS成長率Chemicals 収益成長39.3%収益成長率4.5%将来の株主資本利益率14.33%アナリストカバレッジGood最終更新日15 May 2026今後の成長に関する最新情報お知らせ • Feb 09Victrex plc Provides Earnings Guidance for the First Half and Full Year of Fiscal Year 2024Victrex plc provided earnings guidance for the first half and full year of fiscal year 2024. First half revenue is expected to be lower than the prior year period.The Group previously communicated that progress in revenue for fiscal year 2024.すべての更新を表示Recent updatesDeclared Dividend • May 20First half dividend of UK£0.13 announcedDividend of UK£0.13 is the same as last year. Ex-date: 28th May 2026 Payment date: 26th June 2026 Dividend yield will be 9.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (106% cash payout ratio). The dividend has increased by an average of 2.4% per year over the past 10 years. However, payments have been volatile during that time.お知らせ • May 20Victrex plc Announces Stepping Down of David Thomas as Non-Executive Director, Effective May 18, 2026Victrex PLC announces that David Thomas has informed the Board that he has stepped down as a Non-executive director of the Company with immediate effect on May 18, 2026, due to ill health. David Thomas was appointed as Non-executive director in 2018.お知らせ • May 12Victrex plc Announces Interim Dividend for the Six Months Ended 31 March 2026, Payable on 26 June 2026Victrex plc announced interim dividend for the six months ended 31 March 2026 of 13.42 pence per share will be paid on 26 June 2026 to shareholders on the register at the close of business on 29 May 2026. This dividend will be recognised in the period in which it is approved.お知らせ • Feb 11Victrex plc Announces Changes to Its Board and CommitteeSpirax Group plc announced the appointment of Maria Antoniou, Non-Executive Director and Chair of the Remuneration Committee, has been appointed as a Non-Executive Director of Victrex plc with effect from 1 September 2026. Victrex plc also announced the appointment of Peter Kiernan as non-executive director and David Thomas, non-executive director and Chair of the Audit Committee, will retire from the Board on 1 July 2026, and Peter will succeed David as Chair of the Audit Committee from that date. Peter Kiernan has significant experience in executive and non-executive roles. He had a 30 year career in investment banking with a focus on M&A and general corporate finance advice, including senior roles at S.G. Warburg/UBS, Goldman Sachs, Lazard and Hawkpoint Partners/Canaccord Genuity. He started his career at Peat, Marwick, Mitchell where he qualified as a Chartered Accountant. He holds an MA in Natural Sciences (Chemistry) from Cambridge University. Peter has held several advisory and non-executive positions. He currently holds senior advisory roles at Egon Zehnder and OMERS Private Equity (Europe). Prior non-executive roles include Tungsten Corporation, a public company where he was Audit Committee Chair and Senior Independent Director, Lifeways Group, a private equity owned business where he was Audit Committee Chair and Chair, and Business LDN where he was Chair of the Finance Committee. MariaAntoniou has extensive experience in both executive and non-executive roles within UK plc Boards. She is currently Chief Human Resources Officer at Morgan Advanced Materials plc and a non-executive director at FTSE 100 listed Spirax Group plc. Until last year she was a non-executive director of NATS (the National Air Traffic Service). Maria has a strong background in international industrial businesses, having worked in significant roles at Ford, Jaguar Land Rover and E.ON. Her experience spans across various sectors, including automotive, energy, and advanced materials, which gives her a comprehensive understanding of the challenges and opportunities within industries aligned to Victrex's end-markets.お知らせ • Feb 06Jakob Sigurdsson Steps Down as an Executive Director of Victrex Plc, Effective from February 6, 2026Coats Group PLC announces that it has been notified that Jakob Sigurdsson, a Non-Executive Director of the Company, has on February 6, 2026, stepped down as an Executive Director of Victrex plc.お知らせ • Oct 22Victrex plc, Annual General Meeting, Feb 06, 2026Victrex plc, Annual General Meeting, Feb 06, 2026.お知らせ • Oct 21+ 1 more updateVictrex plc Announces CEO ChangesVictrex plc announced that James Routh will join the Company as Chief Executive Officer with effect from 1 January 2026, succeeding Jakob Sigurdsson. He will join the Board as an Executive Director from the same date. Jakob Sigurdsson will continue to serve on the Victrex Board as Chief Executive until James joins, to support an orderly transition, and then as an Executive Director. Jakob will step down from the Board at the conclusion of the Company's Annual General Meeting on 6 February 2026.お知らせ • Jul 08+ 2 more updatesVictrex plc to Report Fiscal Year 2025 Results on Dec 02, 2025Victrex plc announced that they will report fiscal year 2025 results on Dec 02, 2025お知らせ • Dec 06Victrex plc, Annual General Meeting, Feb 07, 2025Victrex plc, Annual General Meeting, Feb 07, 2025.お知らせ • Dec 03Victrex plc Proposes Final Dividend for the Fiscal Year 2025, Payable on 21 February 2025Victrex plc at its AGM to be held on 7 February 2025, proposed final dividend at 46.14 pence per share (fiscal year 2024: 46.14 pence per share), with an Ex-dividend date: 23 January 2025, Record date: 24 January 2025 and Payment of final dividend: 21 February 2025.お知らせ • Sep 18Victrex plc Announces in Partnership with Maxx Orthopedics Inc, FDA Grants IDE Approval for Freedom Total Knee System with Invibio PEEK-OPTIMA Femoral Component as Staged StudyVictrex plc announced that, in partnership with Maxx Orthopedics Inc, the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for Freedom Total Knee System with Invibio PEEK-OPTIMA Femoral Component, as a staged study. The study, projected to be 120 patients at clinical sites in the US, will compare using the PEEK-OPTIMA Femoral Knee Component to a controlled registry of the same system using traditional metal femoral components. The US study will build on the existing clinical trial for PEEK Knee at sites in Belgium, India and Italy, which has been progressing strongly since the first implant in 2021, with no clinical intervention. A regulatory submission in India is also expected imminently, supporting the potential for a commercial PEEK Knee in the market in 2025.お知らせ • Sep 06Victrex plc to Report Fiscal Year 2024 Results on Dec 03, 2024Victrex plc announced that they will report fiscal year 2024 results on Dec 03, 2024New Risk • May 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 44% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 169% Cash payout ratio: 411% Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (11% net profit margin).Declared Dividend • May 16First half dividend of UK£0.13 announcedDividend of UK£0.13 is the same as last year. Ex-date: 30th May 2024 Payment date: 28th June 2024 Dividend yield will be 4.6%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is not covered by earnings (169% earnings payout ratio) nor is it covered by cash flows (411% cash payout ratio). The dividend has increased by an average of 4.4% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 87% to bring the payout ratio under control. EPS is expected to grow by 143% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.お知らせ • May 15Victrex plc Announces Interim Dividend , Payable on June 28, 2024Victrex plc announced that an interim dividend of 13.42 pence per share (First half 2023: 13.42 pence) will be paid on 28 June 2024 to shareholders on the register at the close of business on 31 May 2024. This dividend will be recognised in the period in which it is approved.New Risk • May 13New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 169% Cash payout ratio: 411% Dividend yield: 4.6% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 169% Cash payout ratio: 411% Minor Risk Profit margins are more than 30% lower than last year (11% net profit margin).お知らせ • Mar 15Victrex plc Appoints Urmi Prasad Richardson as Non-Executive Director, Effective from May 1, 2024Victrex plc announced that Urmi Prasad Richardson has been appointed as a non-executive director of the Board, effective from May 1, 2024. Urmi has a wealth of global experience in executive and non-executive roles over a 25 year period. She has a particular focus on science, medical and innovation based businesses. Urmi is currently President EMEA of Thermo Fisher Scientific, a world leader in serving science, with products which help accelerate life science research and improve patient health. Her executive career includes roles at The Linde Group, where she was Global Head of Healthcare, at Novartis and Foundation Medicine (a Roche company). She started her career with G.D. Searle (a Pfizer company) and has worked throughout Europe and the US. Urmi has extensive experience in strategy, business development and product commercialisation in Europe, Asia and North America. Urmi holds a number of advisory Board roles at unlisted organizations in the sectors of longevity, blockchain, and targeted therapy in oncology. Her previous non-executive roles include Linde Healthcare.お知らせ • Feb 27Victrex plc to Report First Half, 2024 Results on May 13, 2024Victrex plc announced that they will report first half, 2024 results on May 13, 2024お知らせ • Feb 09Victrex plc Provides Earnings Guidance for the First Half and Full Year of Fiscal Year 2024Victrex plc provided earnings guidance for the first half and full year of fiscal year 2024. First half revenue is expected to be lower than the prior year period.The Group previously communicated that progress in revenue for fiscal year 2024.Upcoming Dividend • Jan 18Upcoming dividend of UK£0.46 per share at 4.4% yieldEligible shareholders must have bought the stock before 25 January 2024. Payment date: 23 February 2024. Payout ratio is on the higher end at 84%, and the cash payout ratio is above 100%. Trailing yield: 4.4%. Lower than top quartile of British dividend payers (5.9%). Higher than average of industry peers (3.2%).Reported Earnings • Jan 11Full year 2023 earnings released: EPS: UK£0.71 (vs UK£0.88 in FY 2022)Full year 2023 results: EPS: UK£0.71 (down from UK£0.88 in FY 2022). Revenue: UK£307.0m (down 10.0% from FY 2022). Net income: UK£61.7m (down 19% from FY 2022). Profit margin: 20% (down from 22% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 4.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Reported Earnings • Dec 07Full year 2023 earnings released: EPS: UK£0.71 (vs UK£0.88 in FY 2022)Full year 2023 results: EPS: UK£0.71 (down from UK£0.88 in FY 2022). Revenue: UK£307.0m (down 10.0% from FY 2022). Net income: UK£61.7m (down 19% from FY 2022). Profit margin: 20% (down from 22% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 4.7% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.お知らせ • Dec 05+ 1 more updateVictrex plc, Annual General Meeting, Feb 09, 2024Victrex plc, Annual General Meeting, Feb 09, 2024.Buying Opportunity • Oct 18Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be UK£17.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 2.8%. For the next 3 years, revenue is forecast to grow by 3.3% per annum. Earnings is also forecast to grow by 9.8% per annum over the same time period.お知らせ • Oct 14Victrex Announces New Product Grade Launch, Victrex Pharmaceutical Contact (PC)101 (VICTREX PC101), Developed Exclusively for the Drug Delivery Device MarketVictrex plc have launched a new product grade developed exclusively for Drug Delivery and Pharmaceutical Contact applications. VICTREX PC101™ meets the highest levels of Industry biocompatibility certification for USP Class VI and also meets industry standards such as USP 661 for use in non-implantable pharmaceutical contact applications. This material is available in granules and film and adds value to pharmaceutical production companies and drug delivery device manufacturers by providing access to assured materials for equipment or devices. This has the potential to save them cost, time and reduce risk, ultimately streamlining the commercialisation of their own products. VICTREX PC101™ is a PEEK-based material ideally suited to non-implantable Pharmaceutical contact and drug delivery applications for less than 24-hour tissue contact duration, whether they are production line equipment or primary packaging and end delivery devices. Victrex also offers unparalleled expertise, experience and support to customers, having been the first to commercialise the use of PEEK over 40 years ago. PEEK materials have properties meeting high levels of physical and chemical performance, ideal for applications requiring sterilisation, retention of dimensional stability, or chemical, electrical and temperature resistance. PEEK also meets high levels of mechanical performance, perfectly suited for high strength and miniature parts, wear, abrasion and fatigue exposure. It is also versatile for thermoplastic processing through moulding processes, milling or additive manufacturing. Victrex offer a unique perspective on this market as their medical business, Invibio, has over 20 years of proven clinical history in implantable medical PEEK devices. This insight and experience have enabled them to become a key player in the drug delivery device space over recent years. They are well placed to collaborate with OEMs, engineers and pharma manufacturing companies to support them from design, regulatory approval, manufacture and beyond.Buying Opportunity • Sep 26Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be UK£17.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 2.8%. For the next 3 years, revenue is forecast to grow by 3.4% per annum. Earnings is also forecast to grow by 10% per annum over the same time period.お知らせ • Jul 07Victrex plc to Report Q4, 2023 Results on Dec 04, 2023Victrex plc announced that they will report Q4, 2023 results on Dec 04, 2023Buying Opportunity • Jun 19Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be UK£18.09, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 2.8%. For the next 3 years, revenue is forecast to grow by 4.2% per annum. Earnings is also forecast to grow by 11% per annum over the same time period.Upcoming Dividend • May 18Upcoming dividend of UK£0.13 per share at 3.8% yieldEligible shareholders must have bought the stock before 25 May 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 72% but the company is paying out more than the cash it is generating. Trailing yield: 3.8%. Lower than top quartile of British dividend payers (5.8%). Higher than average of industry peers (2.4%).お知らせ • May 10+ 1 more updateVictrex plc to Report Q2, 2023 Results on May 09, 2023Victrex plc announced that they will report Q2, 2023 results on May 09, 2023Reported Earnings • May 09First half 2023 earnings released: EPS: UK£0.39 (vs UK£0.43 in 1H 2022)First half 2023 results: EPS: UK£0.39 (down from UK£0.43 in 1H 2022). Revenue: UK£162.2m (up 1.3% from 1H 2022). Net income: UK£33.7m (down 11% from 1H 2022). Profit margin: 21% (down from 24% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Upcoming Dividend • Jan 13Upcoming dividend of UK£0.46 per shareEligible shareholders must have bought the stock before 19 January 2023. Payment date: 17 February 2023. Payout ratio is a comfortable 68% but the company is paying out more than the cash it is generating. Trailing yield: 3.4%. Lower than top quartile of British dividend payers (5.4%). Higher than average of industry peers (2.8%).Reported Earnings • Jan 09Full year 2022 earnings released: EPS: UK£0.88 (vs UK£0.84 in FY 2021)Full year 2022 results: EPS: UK£0.88 (up from UK£0.84 in FY 2021). Revenue: UK£341.0m (up 11% from FY 2021). Net income: UK£76.2m (up 4.1% from FY 2021). Profit margin: 22% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 12% per year.Reported Earnings • Dec 07Full year 2022 earnings released: EPS: UK£0.88 (vs UK£0.84 in FY 2021)Full year 2022 results: EPS: UK£0.88 (up from UK£0.84 in FY 2021). Revenue: UK£341.0m (up 11% from FY 2021). Net income: UK£76.2m (up 4.1% from FY 2021). Profit margin: 22% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 10% per year.お知らせ • Dec 06Victrex plc, Annual General Meeting, Feb 10, 2023Victrex plc, Annual General Meeting, Feb 10, 2023.Upcoming Dividend • May 19Upcoming dividend of UK£0.13 per shareEligible shareholders must have bought the stock before 26 May 2022. Payment date: 29 June 2022. Payout ratio is a comfortable 74% but the company is paying out more than the cash it is generating. Trailing yield: 3.5%. Lower than top quartile of British dividend payers (4.8%). Higher than average of industry peers (2.8%).Reported Earnings • May 10First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down UK£40.7m from profit in 1H 2021). Profit margin: (down from 27% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 5.4% compared to a 18% decline forecast for the industry in the United Kingdom.Recent Insider Transactions • Feb 23CEO & Executive Director recently bought UK£53k worth of stockOn the 21st of February, Jakob Sigurdsson bought around 3k shares on-market at roughly UK£18.93 per share. This was the largest purchase by an insider in the last 3 months. Jakob has been a buyer over the last 12 months, purchasing a net total of UK£117k worth in shares.Buying Opportunity • Jan 22Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 5.6%. The fair value is estimated to be UK£27.76, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.5% per annum over the last 3 years. Earnings per share has declined by 23% per annum over the last 3 years.Upcoming Dividend • Jan 20Upcoming dividend of UK£0.96 per shareEligible shareholders must have bought the stock before 27 January 2022. Payment date: 18 February 2022. Payout ratio is a comfortable 71% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of British dividend payers (4.0%). Higher than average of industry peers (2.0%).Reported Earnings • Jan 14Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: UK£0.84 (up from UK£0.63 in FY 2020). Revenue: UK£306.3m (up 15% from FY 2020). Net income: UK£73.2m (up 35% from FY 2020). Profit margin: 24% (up from 20% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 3.7% compared to a 2.8% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Reported Earnings • Dec 08Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: UK£0.84 (up from UK£0.63 in FY 2020). Revenue: UK£306.3m (up 15% from FY 2020). Net income: UK£73.2m (up 35% from FY 2020). Profit margin: 24% (up from 20% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 3.0% compared to a 2.1% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Upcoming Dividend • May 27Upcoming dividend of UK£0.13 per shareEligible shareholders must have bought the stock before 03 June 2021. Payment date: 30 June 2021. Trailing yield: 1.1%. Lower than top quartile of British dividend payers (4.1%). Lower than average of industry peers (1.5%).Reported Earnings • May 12First half 2021 earnings released: EPS UK£0.47 (vs UK£0.48 in 1H 2020)The company reported a soft first half result with weaker earnings, although revenues and profit margins were flat. First half 2021 results: Revenue: UK£150.9m (flat on 1H 2020). Net income: UK£40.7m (down 1.0% from 1H 2020). Profit margin: 27% (in line with 1H 2020). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.Recent Insider Transactions • Mar 02CEO & Executive Director recently bought UK£64k worth of stockOn the 1st of March, Jakob Sigurdsson bought around 3k shares on-market at roughly UK£21.41 per share. This was the largest purchase by an insider in the last 3 months. This was Jakob's only on-market trade for the last 12 months.Analyst Estimate Surprise Post Earnings • Jan 13Revenue beats expectationsRevenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 2.3% compared to a 9.8% decline forecast for the Chemicals industry in the United Kingdom.Analyst Estimate Surprise Post Earnings • Jan 13Revenue beats expectationsRevenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 2.3% compared to a 9.3% decline forecast for the Chemicals industry in the United Kingdom.Reported Earnings • Jan 08Full year 2020 earnings released: EPS UK£0.63The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£266.0m (down 9.5% from FY 2019). Net income: UK£54.2m (down 41% from FY 2019). Profit margin: 20% (down from 31% in FY 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.Analyst Estimate Surprise Post Earnings • Jan 08Revenue beats expectationsRevenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 2.3% compared to a 9.7% decline forecast for the Chemicals industry in the United Kingdom.Is New 90 Day High Low • Jan 07New 90-day high: UK£24.48The company is up 25% from its price of UK£19.63 on 09 October 2020. The British market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£25.25 per share.Is New 90 Day High Low • Dec 23New 90-day high: UK£23.30The company is up 28% from its price of UK£18.24 on 24 September 2020. The British market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£25.37 per share.Reported Earnings • Dec 11Full year 2020 earnings released: EPS UK£0.63The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£266.0m (down 9.5% from FY 2019). Net income: UK£54.2m (down 41% from FY 2019). Profit margin: 20% (down from 31% in FY 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Analyst Estimate Surprise Post Earnings • Dec 11Revenue beats expectationsRevenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 3.4% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.Is New 90 Day High Low • Dec 04New 90-day high: UK£21.12The company is up 9.0% from its price of UK£19.44 on 04 September 2020. The British market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£19.43 per share.業績と収益の成長予測BATS-CHIXE:VCTL - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/2028329454874119/30/2027313414468129/30/20262975446273/31/2026294-204969N/A12/31/202529344970N/A9/30/2025293284971N/A6/30/2025295295778N/A3/31/2025298306585N/A12/31/2024294235884N/A9/30/2024291175184N/A6/30/2024288243267N/A3/31/2024284311351N/A12/31/202329646846N/A9/30/202330762342N/A6/30/2023325671656N/A3/31/2023343722970N/A12/31/2022342743275N/A9/30/2022341763580N/A6/30/2022328734290N/A3/31/20223167049101N/A12/31/20213117267114N/A9/30/20213067385127N/A6/30/20212866473108N/A3/31/2021265546090N/A12/31/2020266545279N/A9/30/2020266544569N/A6/30/2020283725479N/A3/31/2020300896389N/A12/31/201929791N/A85N/A9/30/201929492N/A80N/A6/30/201930096N/A85N/A3/31/201930599N/A91N/A12/31/2018316105N/A110N/A9/30/2018326111N/A129N/A6/30/2018326113N/A127N/A3/31/2018326115N/A125N/A12/31/2017308107N/A121N/A9/30/2017290100N/A118N/A6/30/201727892N/A114N/A3/31/201726684N/A111N/A12/31/201625983N/A97N/A9/30/201625283N/A83N/A6/30/201625181N/A78N/A3/31/201625080N/A72N/A12/31/201525782N/A80N/A9/30/201526484N/A88N/A6/30/201526384N/A96N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: VCTLは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.4% ) よりも高い成長率であると考えられます。収益対市場: VCTL今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: VCTL今後 3 年以内に収益を上げることが予想されます。収益対市場: VCTLの収益 ( 4.5% ) UK市場 ( 4.5% ) よりも低い成長が予測されています。高い収益成長: VCTLの収益 ( 4.5% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: VCTLの 自己資本利益率 は、3年後には低くなると予測されています ( 14.3 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 00:40終値2026/05/21 00:00収益2026/03/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Victrex plc 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。31 アナリスト機関Gunther ZechmannBarclaysKatie RichardsBarclaysJames StewartBarclays28 その他のアナリストを表示
お知らせ • Feb 09Victrex plc Provides Earnings Guidance for the First Half and Full Year of Fiscal Year 2024Victrex plc provided earnings guidance for the first half and full year of fiscal year 2024. First half revenue is expected to be lower than the prior year period.The Group previously communicated that progress in revenue for fiscal year 2024.
Declared Dividend • May 20First half dividend of UK£0.13 announcedDividend of UK£0.13 is the same as last year. Ex-date: 28th May 2026 Payment date: 26th June 2026 Dividend yield will be 9.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (106% cash payout ratio). The dividend has increased by an average of 2.4% per year over the past 10 years. However, payments have been volatile during that time.
お知らせ • May 20Victrex plc Announces Stepping Down of David Thomas as Non-Executive Director, Effective May 18, 2026Victrex PLC announces that David Thomas has informed the Board that he has stepped down as a Non-executive director of the Company with immediate effect on May 18, 2026, due to ill health. David Thomas was appointed as Non-executive director in 2018.
お知らせ • May 12Victrex plc Announces Interim Dividend for the Six Months Ended 31 March 2026, Payable on 26 June 2026Victrex plc announced interim dividend for the six months ended 31 March 2026 of 13.42 pence per share will be paid on 26 June 2026 to shareholders on the register at the close of business on 29 May 2026. This dividend will be recognised in the period in which it is approved.
お知らせ • Feb 11Victrex plc Announces Changes to Its Board and CommitteeSpirax Group plc announced the appointment of Maria Antoniou, Non-Executive Director and Chair of the Remuneration Committee, has been appointed as a Non-Executive Director of Victrex plc with effect from 1 September 2026. Victrex plc also announced the appointment of Peter Kiernan as non-executive director and David Thomas, non-executive director and Chair of the Audit Committee, will retire from the Board on 1 July 2026, and Peter will succeed David as Chair of the Audit Committee from that date. Peter Kiernan has significant experience in executive and non-executive roles. He had a 30 year career in investment banking with a focus on M&A and general corporate finance advice, including senior roles at S.G. Warburg/UBS, Goldman Sachs, Lazard and Hawkpoint Partners/Canaccord Genuity. He started his career at Peat, Marwick, Mitchell where he qualified as a Chartered Accountant. He holds an MA in Natural Sciences (Chemistry) from Cambridge University. Peter has held several advisory and non-executive positions. He currently holds senior advisory roles at Egon Zehnder and OMERS Private Equity (Europe). Prior non-executive roles include Tungsten Corporation, a public company where he was Audit Committee Chair and Senior Independent Director, Lifeways Group, a private equity owned business where he was Audit Committee Chair and Chair, and Business LDN where he was Chair of the Finance Committee. MariaAntoniou has extensive experience in both executive and non-executive roles within UK plc Boards. She is currently Chief Human Resources Officer at Morgan Advanced Materials plc and a non-executive director at FTSE 100 listed Spirax Group plc. Until last year she was a non-executive director of NATS (the National Air Traffic Service). Maria has a strong background in international industrial businesses, having worked in significant roles at Ford, Jaguar Land Rover and E.ON. Her experience spans across various sectors, including automotive, energy, and advanced materials, which gives her a comprehensive understanding of the challenges and opportunities within industries aligned to Victrex's end-markets.
お知らせ • Feb 06Jakob Sigurdsson Steps Down as an Executive Director of Victrex Plc, Effective from February 6, 2026Coats Group PLC announces that it has been notified that Jakob Sigurdsson, a Non-Executive Director of the Company, has on February 6, 2026, stepped down as an Executive Director of Victrex plc.
お知らせ • Oct 22Victrex plc, Annual General Meeting, Feb 06, 2026Victrex plc, Annual General Meeting, Feb 06, 2026.
お知らせ • Oct 21+ 1 more updateVictrex plc Announces CEO ChangesVictrex plc announced that James Routh will join the Company as Chief Executive Officer with effect from 1 January 2026, succeeding Jakob Sigurdsson. He will join the Board as an Executive Director from the same date. Jakob Sigurdsson will continue to serve on the Victrex Board as Chief Executive until James joins, to support an orderly transition, and then as an Executive Director. Jakob will step down from the Board at the conclusion of the Company's Annual General Meeting on 6 February 2026.
お知らせ • Jul 08+ 2 more updatesVictrex plc to Report Fiscal Year 2025 Results on Dec 02, 2025Victrex plc announced that they will report fiscal year 2025 results on Dec 02, 2025
お知らせ • Dec 06Victrex plc, Annual General Meeting, Feb 07, 2025Victrex plc, Annual General Meeting, Feb 07, 2025.
お知らせ • Dec 03Victrex plc Proposes Final Dividend for the Fiscal Year 2025, Payable on 21 February 2025Victrex plc at its AGM to be held on 7 February 2025, proposed final dividend at 46.14 pence per share (fiscal year 2024: 46.14 pence per share), with an Ex-dividend date: 23 January 2025, Record date: 24 January 2025 and Payment of final dividend: 21 February 2025.
お知らせ • Sep 18Victrex plc Announces in Partnership with Maxx Orthopedics Inc, FDA Grants IDE Approval for Freedom Total Knee System with Invibio PEEK-OPTIMA Femoral Component as Staged StudyVictrex plc announced that, in partnership with Maxx Orthopedics Inc, the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for Freedom Total Knee System with Invibio PEEK-OPTIMA Femoral Component, as a staged study. The study, projected to be 120 patients at clinical sites in the US, will compare using the PEEK-OPTIMA Femoral Knee Component to a controlled registry of the same system using traditional metal femoral components. The US study will build on the existing clinical trial for PEEK Knee at sites in Belgium, India and Italy, which has been progressing strongly since the first implant in 2021, with no clinical intervention. A regulatory submission in India is also expected imminently, supporting the potential for a commercial PEEK Knee in the market in 2025.
お知らせ • Sep 06Victrex plc to Report Fiscal Year 2024 Results on Dec 03, 2024Victrex plc announced that they will report fiscal year 2024 results on Dec 03, 2024
New Risk • May 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 44% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 169% Cash payout ratio: 411% Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (11% net profit margin).
Declared Dividend • May 16First half dividend of UK£0.13 announcedDividend of UK£0.13 is the same as last year. Ex-date: 30th May 2024 Payment date: 28th June 2024 Dividend yield will be 4.6%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is not covered by earnings (169% earnings payout ratio) nor is it covered by cash flows (411% cash payout ratio). The dividend has increased by an average of 4.4% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 87% to bring the payout ratio under control. EPS is expected to grow by 143% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.
お知らせ • May 15Victrex plc Announces Interim Dividend , Payable on June 28, 2024Victrex plc announced that an interim dividend of 13.42 pence per share (First half 2023: 13.42 pence) will be paid on 28 June 2024 to shareholders on the register at the close of business on 31 May 2024. This dividend will be recognised in the period in which it is approved.
New Risk • May 13New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Payout ratio: 169% Cash payout ratio: 411% Dividend yield: 4.6% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 169% Cash payout ratio: 411% Minor Risk Profit margins are more than 30% lower than last year (11% net profit margin).
お知らせ • Mar 15Victrex plc Appoints Urmi Prasad Richardson as Non-Executive Director, Effective from May 1, 2024Victrex plc announced that Urmi Prasad Richardson has been appointed as a non-executive director of the Board, effective from May 1, 2024. Urmi has a wealth of global experience in executive and non-executive roles over a 25 year period. She has a particular focus on science, medical and innovation based businesses. Urmi is currently President EMEA of Thermo Fisher Scientific, a world leader in serving science, with products which help accelerate life science research and improve patient health. Her executive career includes roles at The Linde Group, where she was Global Head of Healthcare, at Novartis and Foundation Medicine (a Roche company). She started her career with G.D. Searle (a Pfizer company) and has worked throughout Europe and the US. Urmi has extensive experience in strategy, business development and product commercialisation in Europe, Asia and North America. Urmi holds a number of advisory Board roles at unlisted organizations in the sectors of longevity, blockchain, and targeted therapy in oncology. Her previous non-executive roles include Linde Healthcare.
お知らせ • Feb 27Victrex plc to Report First Half, 2024 Results on May 13, 2024Victrex plc announced that they will report first half, 2024 results on May 13, 2024
お知らせ • Feb 09Victrex plc Provides Earnings Guidance for the First Half and Full Year of Fiscal Year 2024Victrex plc provided earnings guidance for the first half and full year of fiscal year 2024. First half revenue is expected to be lower than the prior year period.The Group previously communicated that progress in revenue for fiscal year 2024.
Upcoming Dividend • Jan 18Upcoming dividend of UK£0.46 per share at 4.4% yieldEligible shareholders must have bought the stock before 25 January 2024. Payment date: 23 February 2024. Payout ratio is on the higher end at 84%, and the cash payout ratio is above 100%. Trailing yield: 4.4%. Lower than top quartile of British dividend payers (5.9%). Higher than average of industry peers (3.2%).
Reported Earnings • Jan 11Full year 2023 earnings released: EPS: UK£0.71 (vs UK£0.88 in FY 2022)Full year 2023 results: EPS: UK£0.71 (down from UK£0.88 in FY 2022). Revenue: UK£307.0m (down 10.0% from FY 2022). Net income: UK£61.7m (down 19% from FY 2022). Profit margin: 20% (down from 22% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 4.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Reported Earnings • Dec 07Full year 2023 earnings released: EPS: UK£0.71 (vs UK£0.88 in FY 2022)Full year 2023 results: EPS: UK£0.71 (down from UK£0.88 in FY 2022). Revenue: UK£307.0m (down 10.0% from FY 2022). Net income: UK£61.7m (down 19% from FY 2022). Profit margin: 20% (down from 22% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 4.7% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
お知らせ • Dec 05+ 1 more updateVictrex plc, Annual General Meeting, Feb 09, 2024Victrex plc, Annual General Meeting, Feb 09, 2024.
Buying Opportunity • Oct 18Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be UK£17.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 2.8%. For the next 3 years, revenue is forecast to grow by 3.3% per annum. Earnings is also forecast to grow by 9.8% per annum over the same time period.
お知らせ • Oct 14Victrex Announces New Product Grade Launch, Victrex Pharmaceutical Contact (PC)101 (VICTREX PC101), Developed Exclusively for the Drug Delivery Device MarketVictrex plc have launched a new product grade developed exclusively for Drug Delivery and Pharmaceutical Contact applications. VICTREX PC101™ meets the highest levels of Industry biocompatibility certification for USP Class VI and also meets industry standards such as USP 661 for use in non-implantable pharmaceutical contact applications. This material is available in granules and film and adds value to pharmaceutical production companies and drug delivery device manufacturers by providing access to assured materials for equipment or devices. This has the potential to save them cost, time and reduce risk, ultimately streamlining the commercialisation of their own products. VICTREX PC101™ is a PEEK-based material ideally suited to non-implantable Pharmaceutical contact and drug delivery applications for less than 24-hour tissue contact duration, whether they are production line equipment or primary packaging and end delivery devices. Victrex also offers unparalleled expertise, experience and support to customers, having been the first to commercialise the use of PEEK over 40 years ago. PEEK materials have properties meeting high levels of physical and chemical performance, ideal for applications requiring sterilisation, retention of dimensional stability, or chemical, electrical and temperature resistance. PEEK also meets high levels of mechanical performance, perfectly suited for high strength and miniature parts, wear, abrasion and fatigue exposure. It is also versatile for thermoplastic processing through moulding processes, milling or additive manufacturing. Victrex offer a unique perspective on this market as their medical business, Invibio, has over 20 years of proven clinical history in implantable medical PEEK devices. This insight and experience have enabled them to become a key player in the drug delivery device space over recent years. They are well placed to collaborate with OEMs, engineers and pharma manufacturing companies to support them from design, regulatory approval, manufacture and beyond.
Buying Opportunity • Sep 26Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be UK£17.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 2.8%. For the next 3 years, revenue is forecast to grow by 3.4% per annum. Earnings is also forecast to grow by 10% per annum over the same time period.
お知らせ • Jul 07Victrex plc to Report Q4, 2023 Results on Dec 04, 2023Victrex plc announced that they will report Q4, 2023 results on Dec 04, 2023
Buying Opportunity • Jun 19Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be UK£18.09, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 2.8%. For the next 3 years, revenue is forecast to grow by 4.2% per annum. Earnings is also forecast to grow by 11% per annum over the same time period.
Upcoming Dividend • May 18Upcoming dividend of UK£0.13 per share at 3.8% yieldEligible shareholders must have bought the stock before 25 May 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 72% but the company is paying out more than the cash it is generating. Trailing yield: 3.8%. Lower than top quartile of British dividend payers (5.8%). Higher than average of industry peers (2.4%).
お知らせ • May 10+ 1 more updateVictrex plc to Report Q2, 2023 Results on May 09, 2023Victrex plc announced that they will report Q2, 2023 results on May 09, 2023
Reported Earnings • May 09First half 2023 earnings released: EPS: UK£0.39 (vs UK£0.43 in 1H 2022)First half 2023 results: EPS: UK£0.39 (down from UK£0.43 in 1H 2022). Revenue: UK£162.2m (up 1.3% from 1H 2022). Net income: UK£33.7m (down 11% from 1H 2022). Profit margin: 21% (down from 24% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Jan 13Upcoming dividend of UK£0.46 per shareEligible shareholders must have bought the stock before 19 January 2023. Payment date: 17 February 2023. Payout ratio is a comfortable 68% but the company is paying out more than the cash it is generating. Trailing yield: 3.4%. Lower than top quartile of British dividend payers (5.4%). Higher than average of industry peers (2.8%).
Reported Earnings • Jan 09Full year 2022 earnings released: EPS: UK£0.88 (vs UK£0.84 in FY 2021)Full year 2022 results: EPS: UK£0.88 (up from UK£0.84 in FY 2021). Revenue: UK£341.0m (up 11% from FY 2021). Net income: UK£76.2m (up 4.1% from FY 2021). Profit margin: 22% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 12% per year.
Reported Earnings • Dec 07Full year 2022 earnings released: EPS: UK£0.88 (vs UK£0.84 in FY 2021)Full year 2022 results: EPS: UK£0.88 (up from UK£0.84 in FY 2021). Revenue: UK£341.0m (up 11% from FY 2021). Net income: UK£76.2m (up 4.1% from FY 2021). Profit margin: 22% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 10% per year.
お知らせ • Dec 06Victrex plc, Annual General Meeting, Feb 10, 2023Victrex plc, Annual General Meeting, Feb 10, 2023.
Upcoming Dividend • May 19Upcoming dividend of UK£0.13 per shareEligible shareholders must have bought the stock before 26 May 2022. Payment date: 29 June 2022. Payout ratio is a comfortable 74% but the company is paying out more than the cash it is generating. Trailing yield: 3.5%. Lower than top quartile of British dividend payers (4.8%). Higher than average of industry peers (2.8%).
Reported Earnings • May 10First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down UK£40.7m from profit in 1H 2021). Profit margin: (down from 27% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 5.4% compared to a 18% decline forecast for the industry in the United Kingdom.
Recent Insider Transactions • Feb 23CEO & Executive Director recently bought UK£53k worth of stockOn the 21st of February, Jakob Sigurdsson bought around 3k shares on-market at roughly UK£18.93 per share. This was the largest purchase by an insider in the last 3 months. Jakob has been a buyer over the last 12 months, purchasing a net total of UK£117k worth in shares.
Buying Opportunity • Jan 22Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 5.6%. The fair value is estimated to be UK£27.76, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.5% per annum over the last 3 years. Earnings per share has declined by 23% per annum over the last 3 years.
Upcoming Dividend • Jan 20Upcoming dividend of UK£0.96 per shareEligible shareholders must have bought the stock before 27 January 2022. Payment date: 18 February 2022. Payout ratio is a comfortable 71% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of British dividend payers (4.0%). Higher than average of industry peers (2.0%).
Reported Earnings • Jan 14Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: UK£0.84 (up from UK£0.63 in FY 2020). Revenue: UK£306.3m (up 15% from FY 2020). Net income: UK£73.2m (up 35% from FY 2020). Profit margin: 24% (up from 20% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 3.7% compared to a 2.8% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Reported Earnings • Dec 08Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: UK£0.84 (up from UK£0.63 in FY 2020). Revenue: UK£306.3m (up 15% from FY 2020). Net income: UK£73.2m (up 35% from FY 2020). Profit margin: 24% (up from 20% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 3.0% compared to a 2.1% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Upcoming Dividend • May 27Upcoming dividend of UK£0.13 per shareEligible shareholders must have bought the stock before 03 June 2021. Payment date: 30 June 2021. Trailing yield: 1.1%. Lower than top quartile of British dividend payers (4.1%). Lower than average of industry peers (1.5%).
Reported Earnings • May 12First half 2021 earnings released: EPS UK£0.47 (vs UK£0.48 in 1H 2020)The company reported a soft first half result with weaker earnings, although revenues and profit margins were flat. First half 2021 results: Revenue: UK£150.9m (flat on 1H 2020). Net income: UK£40.7m (down 1.0% from 1H 2020). Profit margin: 27% (in line with 1H 2020). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
Recent Insider Transactions • Mar 02CEO & Executive Director recently bought UK£64k worth of stockOn the 1st of March, Jakob Sigurdsson bought around 3k shares on-market at roughly UK£21.41 per share. This was the largest purchase by an insider in the last 3 months. This was Jakob's only on-market trade for the last 12 months.
Analyst Estimate Surprise Post Earnings • Jan 13Revenue beats expectationsRevenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 2.3% compared to a 9.8% decline forecast for the Chemicals industry in the United Kingdom.
Analyst Estimate Surprise Post Earnings • Jan 13Revenue beats expectationsRevenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 2.3% compared to a 9.3% decline forecast for the Chemicals industry in the United Kingdom.
Reported Earnings • Jan 08Full year 2020 earnings released: EPS UK£0.63The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£266.0m (down 9.5% from FY 2019). Net income: UK£54.2m (down 41% from FY 2019). Profit margin: 20% (down from 31% in FY 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
Analyst Estimate Surprise Post Earnings • Jan 08Revenue beats expectationsRevenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 2.3% compared to a 9.7% decline forecast for the Chemicals industry in the United Kingdom.
Is New 90 Day High Low • Jan 07New 90-day high: UK£24.48The company is up 25% from its price of UK£19.63 on 09 October 2020. The British market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£25.25 per share.
Is New 90 Day High Low • Dec 23New 90-day high: UK£23.30The company is up 28% from its price of UK£18.24 on 24 September 2020. The British market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£25.37 per share.
Reported Earnings • Dec 11Full year 2020 earnings released: EPS UK£0.63The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£266.0m (down 9.5% from FY 2019). Net income: UK£54.2m (down 41% from FY 2019). Profit margin: 20% (down from 31% in FY 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Analyst Estimate Surprise Post Earnings • Dec 11Revenue beats expectationsRevenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 3.4% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.
Is New 90 Day High Low • Dec 04New 90-day high: UK£21.12The company is up 9.0% from its price of UK£19.44 on 04 September 2020. The British market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£19.43 per share.